Story
Vaccine Stocks Under Pressure After Report of Potential White House Order on Autism Link

Shares of major vaccine manufacturers, particularly Moderna, faced selling pressure Thursday following a report that the Trump administration is considering an executive order related to vaccines and autism. The potential move, attributed to a Bloomberg report, introduces significant regulatory uncertainty for the pharmaceutical sector and could reshape U.S. immunization policy.
Details of the Potential Order
According to the Bloomberg report on August 6, the White House is actively considering an executive order that could be issued as soon as next week. The specific contents of the potential order remain unclear, leaving investors to speculate on its scope, which could range from commissioning new safety studies to altering federal guidance on vaccine schedules.
This development follows a series of moves by the administration that have put the vaccine industry on alert. In January 2026, Health Secretary Robert F. Kennedy Jr. reconstituted a federal autism panel, and in March, a court blocked his earlier attempts to rewrite CDC vaccine guidance.
Market Impact and Stock Exposure
The market's sharpest reaction was seen in Moderna (MRNA), which saw its stock fall 4.28% during the session. Moderna's business model is almost entirely dependent on its mRNA vaccine technology, making it uniquely vulnerable to any policy shift that could erode public trust or weaken vaccine recommendations.
AdOther major vaccine producers are also exposed to the heightened political risk:
- Merck (MRK): The company faces distinct pressure over its Gardasil HPV vaccine. The product was previously subject to litigation involving Health Secretary Kennedy and a $50 million settlement earlier this year, according to the source material.
- Sanofi (SNY): As one of the largest suppliers of childhood vaccines in the U.S., including DTaP combinations, Sanofi's revenue is sensitive to any disruption of the CDC's childhood immunization schedule.
- Pfizer (PFE) and GSK (GSK): Both companies are major players in the global vaccine market with key products like Prevnar 20 and Shingrix, respectively, and would be affected by a broader shift in regulatory policy.
What Investors Are Watching
The primary focus for investors will be the timing and language of any official White House announcement. Even a vaguely worded executive action could impact voluntary vaccine uptake rates and create a sustained legal and reputational overhang for the industry. The market will be closely watching for any clarification on whether the order will mandate new restrictions or simply direct further research.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.